

Bimzelx

Egypt · access guide

Bimzelx access in Egypt: the EDA named-patient pathway

Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.

Quick orientation

Bimzelx (bimekizumab-bkzx) is humanised IgG1 monoclonal antibody that selectively neutralises both IL-17A and IL-17F approved by the US FDA in October 2023 (plaque psoriasis); September 2024 (PsA, AS, nr-axSpA, HS expansion) for moderate-to-severe plaque psoriasis, active psoriatic arthritis, active ankylosing spondylitis, active non-radiographic axial spondyloarthritis, and moderate-to-severe hidradenitis suppurativa in adults. The drug is manufactured by UCB. Egypt patients use the Egyptian Drug Authority named-patient pathway when the locally registered indication, the stocked presentation, or the available payer coverage does not match what the prescribing physician has written. Reserve Meds coordinates the US-side sourcing through a DSCSA-compliant specialty channel, builds the documentation packet your physician needs to file, and orchestrates the logistics into Egypt with a single named coordinator carrying the case end-to-end.

Why Egyptian patients need Bimzelx through the named-patient pathway

Egypt operates a developed pharmaceutical regulatory environment, and Bimzelx may be on the local register, may be in commercial review, or may be entirely absent depending on the stage of UCB's regional rollout. Several patterns drive cross-border requests. First, indication lag: newer indications, particularly the October 2023 (plaque psoriasis); September 2024 (PsA, AS, nr-axSpA, HS expansion) FDA approval timeline, often reach local registration 12 to 36 months later. Second, biomarker-defined eligibility: no specific companion diagnostic; clinical severity scoring (PASI, BSA, Hurley stage in HS, ASDAS in axSpA) can be the diagnostic gate, and where the relevant testing infrastructure is still maturing locally, families coordinate the workup before or in parallel with sourcing. Third, payer coverage: the Universal Health Insurance System (UHIS) where rolled out, the Health Insurance Organisation (HIO), MetLife, AXA, Allianz, Misr Insurance, and private specialty payers each assess specialty therapies case by case, and step-therapy criteria can fail even where the drug is registered. Fourth, stocking gaps: the local agent may not carry every presentation or dose strength reliably, and named-patient import is the operational mechanism that bridges to the exact label the prescriber has written. In each pattern, the named-patient pathway is the legal mechanism that connects a Egyptian-licensed physician's clinical decision with US-sourced, FDA-labelled product for a specific identified patient.

The EDA named-patient pathway for Bimzelx

The Egyptian Drug Authority (EDA), established under Law No. 151 of 2019 with carve-outs from the older Central Administration for Pharmaceutical Affairs (CAPA), administers personal-use and named-patient imports under Pharmacy Law No. 127 of 1955 as amended. Applications route through the EDA portal at edaegypt.gov.eg. The framework permits hospitals and licensed pharmaceutical establishments to import a specific medicine for a specific patient when the medicine is approved by a recognised reference authority (typically the US FDA, EMA, MHRA, PMDA Japan, or Health Canada) and either a clinically equivalent locally registered alternative is not suitable, or the patient's clinical profile does not match the locally approved label.

A complete application for Bimzelx typically includes a clinical justification letter from the treating physician documenting the patient's diagnosis (moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa), severity assessment, prior systemic therapy history, any relevant biomarker results (no specific companion diagnostic; clinical severity scoring (PASI, BSA, Hurley stage in HS, ASDAS in axSpA)), and a clinical rationale for selecting Bimzelx over locally available alternatives. The Egyptian physician's licensure with the Egyptian Medical Syndicate and the Ministry of Health is verified through the application. The packet also specifies the dispensing facility name and license number, the pharmacy in charge of the facility, full product details (brand name, generic name, manufacturer, strength, dosage form, pack size, quantity, intended treatment duration), and a chain-of-custody plan describing how the medicine will move from the US manufacturer through the importer to the dispensing pharmacy.

For Bimzelx specifically, the clinical justification typically frames the case around Bimzelx is the only dual IL-17A/F inhibitor, with superior PASI 100 head-to-head data in BE RADIANT; named-patient routing typically reflects step-therapy failure on TNF or IL-17A class, or specific HS or axSpA cases where the local label has not caught up to the 2024 indication expansion. Approval timelines are typically 10 to 30 business days for routine cases; volatile FX can compress decision windows where families wire USD. The EDA retains discretion on timing, and we do not promise specific durations.

Where Bimzelx gets dispensed in Egypt

A focused group of Egypt institutions handle named-patient specialty-medicine imports as established workflow, with in-house import pharmacy capabilities and physicians experienced with the application set. For Bimzelx specifically, the dispensing facility must accommodate the administration profile: outpatient dermatology, rheumatology, or specialist HS clinic; SC injection in clinic during induction, self-administered at home in maintenance. Tertiary centres that meet this profile include Children's Cancer Hospital Egypt 57357, the Magdi Yacoub Heart Foundation Aswan facility, Cleopatra Hospital Group, As-Salam International Hospital, Dar Al Fouad Hospital, Ain Shams University Specialised Hospital, Kasr Al Ainy (Cairo University), Mansoura University Hospital, and Alexandria University centres.

For physicians at smaller hospitals without internal import infrastructure, the common pattern is to route through a licensed pharmaceutical establishment that holds the import licence and files the EDA application on the prescribing physician's behalf. The medicine then moves under chain-of-custody documentation into the prescribing hospital's outpatient pharmacy for administration.

Real cost picture for Bimzelx in Egypt

US WAC for Bimzelx is approximately USD 5,800 per 160 mg/mL prefilled pen, which translates to an annual WAC in the range of approximately USD 75,000 per year at the maintenance dose for the standard regimen at the labelled dose. The Egyptian pound has been volatile against the US dollar; 1 USD is approximately 48 EGP as of May 2026 (flagged as indicative; we quote USD primary on every firm quote). On that basis, the drug cost alone is materially significant before logistics, the EDA permit fees (which are nominal relative to drug cost), the destination dispensing hospital's administration fees, and Reserve Meds' concierge fee (which is itemised separately on every firm quote).

International cold-chain or ambient logistics into Egypt typically runs in the low to mid four-figure USD range depending on origin, urgency, and packaging requirements. On the insurance side, the Universal Health Insurance System (UHS) where rolled out, the Health Insurance Organisation (HIO), MetLife, AXA, Allianz, Misr Insurance, and private specialty payers each assess named-patient imports case by case. Some reimburse fully when the medicine is on their formulary even if not stocked, some reimburse a percentage subject to copay, and many require pre-authorisation with documented step-therapy failure. We do not promise coverage from any payer. US manufacturer patient assistance programmes do not extend internationally; cross-border patients pay cash or rely on local payer coverage where available.

Clinical evidence and where Bimzelx sits in the treatment landscape

BE VIVID, BE READY, BE SURE, and BE RADIANT (head-to-head versus secukinumab) for plaque psoriasis; BE OPTIMAL and BE COMPLETE for PsA; BE HEARD I and II for HS; BE MOBILE 1 and 2 for axSpA. The drug acts as humanised IgG1 monoclonal antibody that selectively neutralises both IL-17A and IL-17F, and the dosing schedule is for plaque psoriasis: 320 mg SC at weeks 0, 4, 8, 12, 16, then every 8 weeks (every 4 weeks may be considered for patients over 120 kg); for HS: 320 mg every 2 weeks through week 16, then every 2 or 4 weeks; for axSpA and PsA: 160 mg SC every 4 weeks.

Within the treatment landscape, Bimzelx sits alongside IL-17A inhibitors secukinumab (Cosentyx) and ixekizumab (Taltz), IL-23 inhibitors guselkumab (Tremfya), risankizumab (Skyrizi), and tildrakizumab (Ilumya), IL-12/23 inhibitor ustekinumab (Stelara), TNF inhibitors (adalimumab, etanercept, infliximab, certolizumab, golimumab), and JAK inhibitors deucravacitinib, upadacitinib, and tofacitinib. The choice between targeted therapies in this space depends on the patient's full clinical profile, prior therapy exposure, biomarker status, comorbidities, and the prescriber's judgment. Reserve Meds coordinates whichever therapy the physician has selected; we do not steer prescribing.

Safety surveillance for Bimzelx centres on oral candidiasis (more common than with IL-17A-only inhibition, reflecting the broader IL-17 mucosal effect; topical antifungal prophylaxis is routinely discussed), upper respiratory tract infections, injection-site reactions, and the IL-17 class consideration around inflammatory bowel disease. The dispensing facility and the prescribing physician retain clinical responsibility for monitoring and adverse-event management; Reserve Meds does not provide medical care.

Typical timeline for Bimzelx in Egypt

EDA routine processing is typically 10 to 30 business days for routine cases; volatile FX can compress decision windows where families wire USD from a complete filing. End-to-end, most cases complete within 4 to 8 weeks from first complete documentation, with first-of-kind cases and complex biomarker-dependent workups potentially extending further. Where the administration setting is outpatient dermatology, rheumatology, or specialist HS clinic, hospital scheduling and infusion-chair availability are additional sequencing factors that families plan around. We do not promise specific durations; the EDA retains discretion on timing, and shipping windows depend on lane and packaging.

What your Egyptian physician needs to provide

For a Egyptian-licensed specialist prescribing Bimzelx through the EDA pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's diagnosis (moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa), the relevant biomarker work (no specific companion diagnostic; clinical severity scoring (PASI, BSA, Hurley stage in HS, ASDAS in axSpA)), prior systemic therapy history, the FDA-approved indication being invoked, and the clinical rationale for Bimzelx as the appropriate next step.

The letter also specifies the exact dosing plan per the FDA-approved label: for plaque psoriasis: 320 mg SC at weeks 0, 4, 8, 12, 16, then every 8 weeks (every 4 weeks may be considered for patients over 120 kg); for HS: 320 mg every 2 weeks through week 16, then every 2 or 4 weeks; for axSpA and PsA: 160 mg SC every 4 weeks. The monitoring plan references oral candidiasis (more common than with IL-17A-only inhibition, reflecting the broader IL-17 mucosal effect; topical antifungal prophylaxis is routinely discussed), upper respiratory tract infections, injection-site reactions, and the IL-17 class consideration around inflammatory bowel disease. The treating physician's licence number with the Egyptian Medical Syndicate and the Ministry of Health, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. Where biomarker testing requires reference-lab coordination, the physician documents the assay used and the report; Reserve Meds can route this through a US-side reference laboratory where the regional pathway is unavailable.

Common questions about Bimzelx in Egypt

Will the Universal Health Insurance System (UHS) where rolled out or other major Egyptian insurers cover Bimzelx? Each insurer assesses named-patient imports case by case. Some reimburse fully when Bimzelx is on their formulary even if not currently stocked; others assess based on step-therapy criteria and biomarker documentation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you, your physician, or your hospital. We do not promise coverage from any payer.

Is Bimzelx registered locally in Egypt? Local registration status changes as UCB pursues regional rollout; even where the drug is registered, the specific indication, presentation, or dosing strength your prescriber has written may not align with what is currently stocked. The EDA named-patient pathway exists precisely to bridge these gaps for individually identified patients.

What about competitor therapies? The treatment landscape includes IL-17A inhibitors secukinumab (Cosentyx) and ixekizumab (Taltz), IL-23 inhibitors guselkumab (Tremfya), risankizumab (Skyrizi), and tildrakizumab (Ilumya), IL-12/23 inhibitor ustekinumab (Stelara), TNF inhibitors (adalimumab, etanercept, infliximab, certolizumab, golimumab), and JAK inhibitors deucravacitinib, upadacitinib, and tofacitinib. The choice depends on the patient's full clinical profile and prescriber judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not steer prescribing decisions and we do not have a financial relationship with any specific manufacturer.

How is the cold chain or storage managed? Bimzelx ships in validated packaging with continuous temperature logging through the lane where cold-chain handling applies. The handoff ends at the dispensing pharmacy; home storage instructions, where the patient takes the medicine home for self-administration, are part of the patient onboarding kit.

Do US manufacturer patient assistance programmes (such as UCB co-pay or PAP programmes) extend to Egypt patients? No. US-resident patient assistance programmes are limited to US-resident patients with US prescription coverage by programme design. Cross-border patients pay cash for the drug and the coordination fee, with local payer reimbursement assessed separately.

Can the case be resupplied year over year if the patient responds? Yes. Reserve Meds maintains the case file and re-files EDA permits at the relevant intervals (or coordinates with the dispensing hospital's pharmacy if they hold the permit). Patients on long-term therapy typically settle into a quarterly or biannual resupply cadence after the first cycle.

What is the administration setting? Outpatient dermatology, rheumatology, or specialist hs clinic; sc injection in clinic during induction, self-administered at home in maintenance.

My physician is at a smaller hospital without an internal import pharmacy. Can the case still proceed? Yes. The common pattern is to route through a Dubai, Riyadh, Mumbai, Cairo, Karachi, or other regional licensed pharmaceutical establishment that holds the import licence and files the EDA application on the prescribing physician's behalf. The medicine moves into the prescribing hospital's outpatient pharmacy under chain-of-custody documentation.

Where Reserve Meds fits in Bimzelx cases

Reserve Meds is a US-based concierge coordinator. We do not replace your Egyptian specialist, we do not replace the EDA, and we do not replace your dispensing pharmacy. For Bimzelx specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate logistics into Egypt, and assign a single named coordinator through the case. The pharmacist-of-record review, prescription validation, biomarker confirmation, and physician sign-off are the recurring operational fundamentals for this drug.

Reserve Meds's role

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.

Reserve Meds

reserved for you.

Composite case examples. This document is for general information only and does not constitute medical advice. Please consult your treating physician.

Reserve Meds is in pre-launch. Published timelines and cost ranges are indicative, not guarantees.

reservemeds.com · hello@reservemeds.com